Todd Asset Management LLC Sells 259,460 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Todd Asset Management LLC decreased its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 6.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,777,137 shares of the company’s stock after selling 259,460 shares during the period. Teva Pharmaceutical Industries makes up 2.3% of Todd Asset Management LLC’s portfolio, making the stock its largest holding. Todd Asset Management LLC’s holdings in Teva Pharmaceutical Industries were worth $117,885,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Phoenix Financial Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 9.4% in the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock worth $834,164,000 after acquiring an additional 3,533,800 shares during the last quarter. National Pension Service grew its stake in shares of Teva Pharmaceutical Industries by 24.2% in the third quarter. National Pension Service now owns 2,073,293 shares of the company’s stock worth $41,881,000 after acquiring an additional 404,526 shares during the last quarter. Public Sector Pension Investment Board grew its stake in shares of Teva Pharmaceutical Industries by 11.5% in the third quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock worth $13,543,000 after acquiring an additional 69,000 shares during the last quarter. Teacher Retirement System of Texas grew its stake in shares of Teva Pharmaceutical Industries by 11.2% in the third quarter. Teacher Retirement System of Texas now owns 697,574 shares of the company’s stock worth $14,091,000 after acquiring an additional 69,994 shares during the last quarter. Finally, Thrivent Financial for Lutherans acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth $4,029,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Ratings Changes

TEVA has been the topic of several research analyst reports. Bank of America raised their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. UBS Group raised their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. The Goldman Sachs Group raised their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Piper Sandler restated an “overweight” rating and issued a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. Finally, Scotiabank raised their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research note on Thursday, January 29th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus price target of $41.78.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 144,180 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, May 1st. The stock was sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the completion of the transaction, the insider directly owned 80,760 shares of the company’s stock, valued at approximately $2,825,792.40. This trade represents a 64.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Christine Fox sold 21,258 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $35.31, for a total value of $750,619.98. Following the transaction, the executive vice president directly owned 63,647 shares of the company’s stock, valued at approximately $2,247,375.57. The trade was a 25.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 1,280,269 shares of company stock valued at $42,755,980. Insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 0.1%

Shares of TEVA stock opened at $34.04 on Monday. The stock has a market cap of $39.13 billion, a P/E ratio of 25.59, a price-to-earnings-growth ratio of 3.29 and a beta of 0.86. Teva Pharmaceutical Industries Ltd. has a one year low of $14.99 and a one year high of $37.35. The stock has a fifty day moving average price of $31.83 and a 200 day moving average price of $30.99. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The firm had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. Analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.49 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.